Swedencare Ab · OMXSTO:SECARE
Swedencare Ab — Q4 2023 Earnings Presentation
13 slides from Swedencare Ab's earnings presentation, Feb 15, 2024
Slide 1: Q4/Year End Report January – December 2023
Q4/YEAR END REPORT Presentation January – December 2023 CEO Håkan Lagerberg CFO Jenny Graflind
Slide 2: Q4 2023 Highlights
Q4 2023 Highlights Continued strong demand and initiatives yielding results – 23% organic growth for Q4 Sales record – Growth in all Channels and Regions Organic growth 23% for Q and 15% for full year Strong cash flow – 93% cash conversion from EBITDA, minority acquisition and 75 MSEK amortization 8
Slide 3: ESG 2023
ESG 2023 Completed the implementation of a sustainability platform where relevant KPI´s have been carefully selected. Conducted a life cycle analysis for ProDen PlaqueOff® 60g which has provided us with a deeper understanding of the product´s environmental impact. Obtained certification as a Nasdaq
Slide 4: Net sales and Operational EBITDA (MSEK)
Operational Net sales (MSEK) EBITDA (MSEK) 700 600 140 % 13% 26 120 500 100 400 80 300 24,2% 21,6% 497.4 627.2 60 200 40 100 20 0 0 Q4 2022 Q4 2023 Q4 2022 Q4 2023
Slide 5: Key Performance Indicators Q4 2023
Key Performance Indicators Q4 2023
Slide 6: Key Performance Indicators YTD 2023
Key Performance Indicators YTD 2023
Slide 7: Rolling 4 Quarters
Rolling 4 Quarters Qi @2. Q3 A4 At a a8 4A Kt 2020 2021 2022 2023 HE Net revenue EBITDA (EE Operational EBITDA #8 SWEDENCARE
Slide 8: Product- and Brandsplit
Product- and Brandsplit OTHER PHARMA 6 % PRODEN PLAQUEOFF® nutravet® “ (8%) 12% come 4% (4%) ° (10%) 15% (7%) Pet MD 11% (11%) TOPICALS/ am DERMATOLOGY oe PlaqueOff 24% AY NaturVet® 15% (12%) (28%) Q4 2023 25% (45%) Q4 2023 PRIVATE/CO LABEL, 18% (6%) INUTRACEUTICALS 54% (54%) Rx Vitamins 5% (7%) 7%
Slide 9: Net Sales North America 474.7 MSEK, 19% growth
Net Sales North America 474.7 MSEK, 19% growth North America – 76% of total net revenue • Strong quarter in all channels, VET picking up steam - 2024 • Vetio South & Vetio North – Expected recovery in Q4 due to successful strategy in the beginning of the year • PetMD +44%, ProDen PlaqueOff® +46%, Na
Slide 10: Net Sales Europe 134.3 MSEK, 53% growth
Net Sales Europe 134.3 MSEK, 53% growth Europe – 21% of total net revenue • Market demand high on all channels • Double digit growth on most of the European markets and some exceptional, Spain +57% and Ireland 63%. GR, FR, Innovet and nutravet best Q for the year • Vetio UK (CVP), surpassed its comb
Slide 11: Net Sales Exports 18.2 MSEK, 70% growth
Net Sales Exports 18.2 MSEK, 70% growth Rest of the World – 3% of total revenue • Development project for Vetio N from Asian customer • Increased sales and interest of Flavorpal® • NaturVet and RX Vitamins primarily Asian sales • Solid ProDen PlaqueOff® sales • China list SDC Ireland production site
Slide 12: Priorities 2024
Priorities 2024 Growth and profitability and lowering debt level Execution on synergies, sales and cost savings Continued move from external to internal Strong pipe line - Product launches continues all year Co-op and M&A opportunities Strong start of 2024
Slide 13: Thank You for participating! Q&A
Thank You for participating! Q&A